QUANTIFY CANCER
MRD detection requires overcoming both biological and logistical challenges.
Low levels of ctDNA in
early-stage cancer¹
ctDNA is challenging to detect in its earliest stages, requiring a highly sensitive approach to accurately detect and quantify cancer
Current assays only track
a small subset of variants²
Genomic-only information provides a narrow view of cancer, but a more comprehensive view is needed to understand cancer evolution
Background noise
impacts accuracy¹
Genomic-based approaches can be impacted by biological noise, including clonal hematopoiesis, that impacts accuracy of ctDNA detection
Tissue-informed testing
has logistical challenges¹
Tissue-informed testing has several logistical challenges, including tissue insufficiency, increased TAT due to procurement and processing, and invasive procedures
Home Guardant Infinity™ for BioPharma Guardant360® CDx for BioPharma InfinityAI for BioPharma
~40%
ctDNA, circulating tumor DNA; mNSCLC, metastatic non-small cell lung cancer; MRD, molecular residual disease; TAT, turnaround time.
InfinityAI is not a standalone customer product. “Powered by InfinityAI” refers to Guardant Health artificial intelligence and machine learning technology used in development of product features. These features are reported as professional service and have not been cleared or approved by the US FDA.
of first-line mNSCLC patients have insufficient tissue for comprehensive genomic profiling3
Guardant Infinity is for Research Use Only. Not for use in diagnostic procedures